Lobeline effects on tonic and methamphetamine-induced dopamine release
about
The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophyLobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Pharmacological approaches to methamphetamine dependence: a focused review.High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin bindingPhenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2Modulation of aggressive behavior in mice by nicotinic receptor subtypes.Novel medications to treat addictive disordersTetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivoCholinergic functioning in stimulant addiction: implications for medications development.Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens.Development of serotonin transporter reuptake inhibition assays using JAR cells.Increased Absolute Glutamate Concentrations and Glutamate-to-Creatine Ratios in Patients With Methamphetamine Use Disorders
P2860
Q26827638-2CDC4755-A88E-4BCC-8365-F0B1F48782F0Q33613631-B8F51E68-765A-4AC9-B28F-DFD20A0FD755Q33738102-0604176E-B4FC-46F2-8158-D91363B66047Q33854736-3154B81F-9702-4CE5-A7F4-21F87C563537Q33906303-00B30ADE-E664-497D-A5EB-B58B33586E51Q34262912-EF0E0CC8-7ADB-4965-BF19-F91BA6E4F96EQ34702317-BDEA2A39-4B15-4E75-92F6-C125AF143625Q36144924-6B357DBD-A31C-4EA6-B4AD-8E8B589E1BA4Q37029633-941358F0-774B-4825-86A5-669DD6B58D87Q37190441-625E4157-BC19-4833-816D-202A0D5C9828Q37227997-4993A6C2-D4A7-4F48-B9FD-6D186CF105E5Q37618780-451B4607-4F00-4757-97F4-8BDF3C38AF9EQ40761247-A5501DDC-AEB9-4AF2-9BDE-CD45D0EBB548Q52648128-39585C5B-79B8-421E-9527-39E48985FFC9Q58780691-061626B2-634A-4010-951A-0D6483331E3A
P2860
Lobeline effects on tonic and methamphetamine-induced dopamine release
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lobeline effects on tonic and methamphetamine-induced dopamine release
@ast
Lobeline effects on tonic and methamphetamine-induced dopamine release
@en
Lobeline effects on tonic and methamphetamine-induced dopamine release
@nl
type
label
Lobeline effects on tonic and methamphetamine-induced dopamine release
@ast
Lobeline effects on tonic and methamphetamine-induced dopamine release
@en
Lobeline effects on tonic and methamphetamine-induced dopamine release
@nl
prefLabel
Lobeline effects on tonic and methamphetamine-induced dopamine release
@ast
Lobeline effects on tonic and methamphetamine-induced dopamine release
@en
Lobeline effects on tonic and methamphetamine-induced dopamine release
@nl
P2093
P2860
P1476
Lobeline effects on tonic and methamphetamine-induced dopamine release
@en
P2093
Aaron Janowsky
Amy J Eshleman
Clare J Wilhelm
Robert A Johnson
P2860
P304
P356
10.1016/J.BCP.2007.11.019
P407
P577
2008-03-15T00:00:00Z